CA21140 - Interception of oral cancer development (INTERCEPTOR)

The INTERCEPT (INTercEption of oRal CancEr develoPmenT) COST Action addresses the challenge of unmet oral cancer prevention and bring new paradigm to disease management of oral potentially malignant disorders (OPMD). Relying on excellent translational research, patient care and education in Europe (EU) in the field of cancer medicine, INTERCEPT will develop future strategies of personalized OPMD preventive and care approaches. Pluridisciplinary expertise will involve and target a spectrum of keys actors to ensure a long-term success.

At the level of the patients’ medical histories, the Action will perform disease trajectory analysis based on healthcare data.

At the level of the caregivers, the Action will improve patient’s pathway by developing electronic-health tools for patients’ monitoring. Unbiased techniques to improve early detection of OPMD will be explored.

At the level of the clinical and translational researchers, the Action will:

• develop preclinical models to evaluate new pharmacological approaches to cancer interception;

• coordinate a network of centers to work on prospective clinical trials evaluating new preventive agents;

• coordinate the development of standardized procedures for sample collection, and comprehensively characterize OPMD to improve patient stratification.

At the level of the citizens, the Action will study the socio-economic and ethical impacts of developing personalized preventive medicine and work with policy makers and regulatory bodies to transfer our findings into real-life application.

The network will bring together 108 participants from 23 COST countries, and will facilitate the collaborative research work between involved stakeholders and promote efficient preventive measures for all citizens across EU.